Haining Huang

Company: Cytimm Therapeutics

Job title: CEO

Seminars:

Analyzing Natural Glycosylated PEG-IL2v with Treg Bias for ALS & Autoimmune Diseases 11:00 am

Designing the best IL-2v for chronic inflammatory diseases CTM201 is the first long-acting PEG-IL2v without compromising its bioactivity Examining the PK/PD and safety profiles of CTM201 in ALS patientsRead more

day: Day 2 Treg Modulators Track AM

Roundtable Discussion: Discussing Alternative Functions of Tregs to Unearth New Perspectives of Disease Treatment 12:00 pm

Exploring the non-immunosuppressive functions of Tregs to accelerate treatment development for inflammatory diseases Analyzing mechanistic insights of Treg modulators to evaluate their effectiveness in combating inflammation Discussing the use of anti-inflammatory antibodies in combating diseases such as IBDRead more

day: Day 1 Treg Modulators track AM

Panel Discussion: Shaping the Future of Treg Modulators to Produce Cutting-Edge Therapies 2:30 pm

Exploring novel Treg modulators beyond IL-2 (including IL-35 and TNFR-2 agonists) to uncover new therapeutic capabilities Investigating emerging small molecules and biologic modulators to supercharge therapeutic development Discovering antibody-specific Treg modulationRead more

day: Day 1 Treg Modulatorstrack